Compare
Phio Pharmaceuticals Corp. vs Emmaus Life Sciences, Inc. vs Moleculin Biotech, Inc. vs Nexentis Technologies Inc.
| Latest fiscal year | Phio Pharmaceuticals Corp. PHIO | Emmaus Life Sciences, Inc. EMMA | Moleculin Biotech, Inc. MBRX | Nexentis Technologies Inc. NXTS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $12.45M | $0 | n/a |
| Revenue growth (YoY) | n/a | -25.2% | n/a | n/a |
| Gross margin | n/a | 93.1% | n/a | n/a |
| Operating margin | n/a | 1.9% | n/a | n/a |
| Net margin | n/a | -60.2% | n/a | n/a |
| Net income | -$8.70M | -$7.49M | -$33.56M | -$4.00M |
| EPS (Diluted) | n/a | -$0.12 | n/a | -$8.61 |
| Operating cash flow | -$7.98M | -$11.0K | -$22.73M | -$3.81M |
| Free cash flow | -$7.99M | -$12.0K | -$22.73M | -$3.82M |
| Cash & equivalents | $21.03M | $2.13M | $8.88M | $3.83M |
| Total assets | $21.49M | $21.44M | $22.13M | $20.41M |
| Total liabilities | $1.34M | $85.04M | $7.12M | $4.67M |
| Shareholders' equity | $20.15M | -$63.61M | $15.01M | $16.01M |
| Return on year-end equity | -43.2% | n/a | -223.6% | -25.0% |
| Shares outstanding | 11.62M | 70.19M | 3.20M | 2.77M |
Revenue, most recent five fiscal years
| Fiscal year | Phio Pharmaceuticals Corp. | Emmaus Life Sciences, Inc. | Moleculin Biotech, Inc. | Nexentis Technologies Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2020-12-31 | $12.45M Ended 2025-12-31 | $0 Ended 2025-12-31 | $210.0K Ended 2024-12-31 |
| 1 year earlier | $21.0K Ended 2019-12-31 | $16.65M Ended 2024-12-31 | $0 Ended 2024-12-31 | $263.0K Ended 2023-12-31 |
| 2 years earlier | $138.0K Ended 2018-12-31 | $29.60M Ended 2023-12-31 | $0 Ended 2023-12-31 | $394.0K Ended 2022-12-31 |
| 3 years earlier | $15.0K Ended 2017-12-31 | $18.39M Ended 2022-12-31 | $0 Ended 2022-12-31 | $438.1K Ended 2021-12-31 |
| 4 years earlier | $19.0K Ended 2016-12-31 | $20.61M Ended 2021-12-31 | $0 Ended 2021-12-31 | $232.3K Ended 2020-12-31 |